# Codexis

Type: Company (CDXS)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/codexis
Canonical HTML page: https://getbiobrief.com/entity/codexis

## Timeline

- **2026-03-24**: Analyst Sentiment Review — Major firms maintain ratings, citing steady execution of the strategic pivot.
- **2026-03-12**: 2026 Guidance Issued — Management outlines $72M-$76M revenue target driven by ECO Synthesis.
- **2026-03-11**: Q4 2025 Earnings Release — Codexis reports significant beats on both top and bottom lines.

## Recent coverage (3 stories)

### Codexis Sustains Analyst Confidence Following Q4 Beat and 2026 Revenue Guidance
2026-03-24 23:00:34 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Codexis (CDXS) has maintained steady analyst sentiment following a strong Q4 2025 performance that exceeded revenue and earnings expectations. The company’s strategic pivot toward its ECO Synthesis platform for RNA manufacturing is gaining commercial traction, supported by a 2026 revenue target of $72M–$76M.
Full story: https://getbiobrief.com/story/codexis-cdxs-earnings-analyst-sentiment-2026

### Wall Street Zen Upgrades Codexis and Enovis on Strong 2026 Growth Outlooks
2026-03-16 06:31:28 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen has upgraded the stock ratings for Codexis (CDXS) and Enovis (ENOV), signaling increased confidence in their long-term strategic pivots. The upgrades follow robust quarterly performances and the unveiling of ambitious 2026 revenue targets driven by high-margin technological innovations.
Full story: https://getbiobrief.com/story/codexis-enovis-stock-upgrades-wall-street-zen

### Biotech Sector Pivots: Codexis, Elutia, and Biote Signal Strategic Shifts
2026-03-12 00:14:38 · Sentiment: Positive · Impact: 6/10 · Sources: 9

Q4 2025 earnings for specialized biotech firms reveal a sector-wide shift toward high-margin manufacturing and strategic divestitures. While Codexis capitalizes on its Merck partnership and ECOsynthesis platform, Elutia has cleared its debt through an $88 million divestiture to Boston Scientific.
Full story: https://getbiobrief.com/story/biotech-q4-2025-earnings-strategic-pivots

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.